Antares Pharma Company Profile (NASDAQ:ATRS)

About Antares Pharma

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: ATRS
  • CUSIP: 03664210
Key Metrics:
  • Previous Close: $1.66
  • 50 Day Moving Average: $1.29
  • 200 Day Moving Average: $1.04
  • 52-Week Range: $0.67 - $1.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.44
  • P/E Growth: -0.14
  • Market Cap: $257.40M
  • Outstanding Shares: 155,058,000
  • Beta: 0.77
Profitability:
  • Net Margins: -54.98%
  • Return on Equity: -41.06%
  • Return on Assets: -31.68%
Debt:
  • Current Ratio: 2.44%
  • Quick Ratio: 2.13%
Additional Links:
Companies Related to Antares Pharma:

Analyst Ratings

Consensus Ratings for Antares Pharma (NASDAQ:ATRS) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (80.72% upside)

Analysts' Ratings History for Antares Pharma (NASDAQ:ATRS)
Show:
DateFirmActionRatingPrice TargetDetails
8/13/2016Piper Jaffray Cos.Reiterated RatingOverweight$3.00 -> $2.00View Rating Details
5/10/2016Jefferies GroupReiterated RatingBuy$3.00View Rating Details
9/25/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$4.00View Rating Details
10/22/2014JMP SecuritiesInitiated CoverageOutperform$4.00View Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Antares Pharma (NASDAQ:ATRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/9/2016Q216($0.04)($0.04)$11.00 million$12.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details
11/5/2015Q3 15($0.03)($0.04)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details
11/6/2014($0.07)($0.05)ViewN/AView Earnings Details
8/7/2014Q214($0.07)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details
5/9/2014Q114($0.05)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Antares Pharma (NASDAQ:ATRS)
Current Year EPS Consensus Estimate: $-0.15 EPS
Next Year EPS Consensus Estimate: $-0.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.04)($0.04)($0.04)
Q3 20162($0.03)$0.02($0.01)
Q4 20161($0.03)($0.03)($0.03)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Antares Pharma (NASDAQ:ATRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Antares Pharma (NASDAQ:ATRS)
Insider Ownership Percentage: 10.77%
Institutional Ownership Percentage: 36.34%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.00View SEC Filing  
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00View SEC Filing  
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00View SEC Filing  
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00View SEC Filing  
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.00View SEC Filing  
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00View SEC Filing  
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00View SEC Filing  
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00View SEC Filing  
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00View SEC Filing  
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Antares Pharma (NASDAQ:ATRS)
DateHeadline
News IconKeen Investors Find News on Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - September 24 at 3:34 PM
streetinsider.com logoAntares Pharma (ATRS) Announces Safety Data from QST-15-005 Study (NASDAQ:ATRS)
www.streetinsider.com - September 23 at 4:03 PM
4-traders.com logoAntares Pharma : Announces Completion of the Quickshot Testosterone Clinical Program READ (NASDAQ:ATRS)
www.4-traders.com - September 23 at 4:03 PM
News IconActive News in Reviews- Antares Pharma (NASDAQ:ATRS), Ionis Pharmaceuticals (NASDAQ:IONS) - Seneca Globe (NASDAQ:ATRS)
www.senecaglobe.com - September 23 at 8:37 AM
News IconUnder the Microscope, Zeroing in at Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - September 23 at 8:37 AM
News IconPenny Stock Investors Keen on Shares of Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - September 22 at 9:33 AM
streetinsider.com logoAntares Pharma (ATRS) Announces Safety Data from QST-15-005 Study - StreetInsider.com (NASDAQ:ATRS)
www.streetinsider.com - September 22 at 9:33 AM
finance.yahoo.com logoAntares Pharma Announces Completion of the QuickShot Testosterone Clinical Program (NASDAQ:ATRS)
finance.yahoo.com - September 22 at 9:33 AM
publicnow.com logoAntares Pharma Announces Completion of the Quickshot Testosterone Clinical Program READ (NASDAQ:ATRS)
www.publicnow.com - September 22 at 9:33 AM
feeds.reuters.com logoBRIEF-Antares Pharma completes QuickShot Testosterone clinical program (NASDAQ:ATRS)
feeds.reuters.com - September 22 at 7:37 AM
News IconLennar Corporation (NYSE:LEN) & Antares Pharma Inc (NASDAQ:ATRS) Stocks Buzz - Money News (NASDAQ:ATRS)
www.newsismoney.com - September 21 at 8:23 AM
News IconPenny Stock Investors Take an Interest in Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - September 20 at 3:36 PM
finance.yahoo.com logoAntares Pharma to Present at the Ladenburg Thalmann 2016 Healthcare Conference (NASDAQ:ATRS)
finance.yahoo.com - September 20 at 9:33 AM
investornewswire.com logoAntares Pharma, Inc. (NASDAQ:ATRS) Posted A Surprise Factor Of ... - Investor Newswire (NASDAQ:ATRS)
www.investornewswire.com - September 17 at 8:28 AM
News IconKeen Investors Seek Information on Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - September 17 at 8:28 AM
News IconStock Update, a Closer Look at Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - September 15 at 3:40 PM
News IconAntares Pharma Incorporated (NASDAQ:ATRS) Shorted Shares Increased 0.77% After Market Selling - Post News (NASDAQ:ATRS)
www.kentuckypostnews.com - September 15 at 3:40 PM
biz.yahoo.com logoANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:ATRS)
biz.yahoo.com - September 14 at 8:53 PM
News IconKeen Investors Narrowing Their Focus on Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - September 14 at 3:40 PM
realistinvestor.com logoAntares Pharma, Inc. (NASDAQ:ATRS) Is Expected To Post EPS Of $-0.02 - RealistInvestor.com (NASDAQ:ATRS)
www.realistinvestor.com - September 13 at 8:28 AM
capitalcube.com logoETF’s with exposure to Antares Pharma, Inc. : September 12, 2016 (NASDAQ:ATRS)
www.capitalcube.com - September 12 at 3:36 PM
News IconEarnings Analysis & Update for Antares Pharma, Inc. (NASDAQ:ATRS)? - Frisco Fastball (NASDAQ:ATRS)
friscofastball.com - September 9 at 3:37 PM
biz.yahoo.com logoANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ATRS)
biz.yahoo.com - September 7 at 8:47 PM
News IconAntares Pharma Inc (NASDAQ:ATRS) Might Have The Edge Over Adamis Pharmaceuticals Corp (NASDAQ:ADMP) In The Generic Epi Space (NASDAQ:ATRS)
streetregister.com - August 31 at 3:36 PM
capitalcube.com logoETF’s with exposure to Antares Pharma, Inc. : August 30, 2016 (NASDAQ:ATRS)
www.capitalcube.com - August 30 at 3:36 PM
4-traders.com logoAntares Pharma : to Report Second Quarter Financial and Operating Results and Host Webcast and Conference Call READ (NASDAQ:ATRS)
www.4-traders.com - August 30 at 10:14 AM
publicnow.com logoAntares Pharma Reports Second Quarter 2016 Operating And Financial Results READ (NASDAQ:ATRS)
www.publicnow.com - August 30 at 10:14 AM
publicnow.com logoAntares Pharma to Report Second Quarter Financial and Operating Results and Host Webcast and Conference Call READ (NASDAQ:ATRS)
www.publicnow.com - August 30 at 10:14 AM
investing.com logoU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.58% (NASDAQ:ATRS)
www.investing.com - August 29 at 9:18 PM
News IconNASDAQ Composite Index Closes Off Highs after US Consumer Spending Rises in July (NASDAQ:ATRS)
www.economiccalendar.com - August 29 at 9:18 PM
News IconAntares Pharma, Inc. (NASDAQ:ATRS) will report its next earnings on Nov 3 - Nov 7 (Est.) - Newburg Press (NASDAQ:ATRS)
newburghpress.com - August 29 at 4:14 PM
seekingalpha.com logoAntares Pharmaceuticals: The Stock To Buy On EpiPen Issues - Seeking Alpha (NASDAQ:ATRS)
seekingalpha.com - August 29 at 4:14 PM
News IconRetreated Mix Cap Active Movers: MannKind (NASDAQ:MNKD), Antares Pharma (NASDAQ:ATRS), Nymox ... - Seneca Globe (NASDAQ:ATRS)
www.senecaglobe.com - August 26 at 11:46 AM
News IconNotable Stocks to Watch: Hudson Technologies, Inc. (NASDAQ:HDSN), Antares Pharma Inc (NASDAQ:ATRS) - NYSE Journal (press release) (NASDAQ:ATRS)
stockznews.com - August 24 at 3:39 PM
benzinga.com logoHave You Heard About This Generic EpiPen Maker? - Benzinga (NASDAQ:ATRS)
www.benzinga.com - August 24 at 3:39 PM
News IconMagnifying Stocks of Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - August 23 at 3:42 PM
News IconShares Going Higher in Session: Antares Pharma Inc. (NASDAQ:ATRS) - Post News (NASDAQ:ATRS)
www.kentuckypostnews.com - August 23 at 3:42 PM
News IconLet's Take a Closer Look at Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - August 22 at 8:44 PM
investornewswire.com logoWill Antares Pharma, Inc. (NASDAQ:ATRS) Hit $3 Price Target? - Investor Newswire (NASDAQ:ATRS)
www.investornewswire.com - August 21 at 8:22 AM
News IconSmall Cap Insight on Shares of Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - August 20 at 3:39 PM
finance.yahoo.com logoANTARES PHARMA, INC. Financials (NASDAQ:ATRS)
finance.yahoo.com - August 19 at 4:17 PM
zacks.com logoLabCorp Q2 Results Strong, Sequenom Buyout Raises Hope (NASDAQ:ATRS)
www.zacks.com - August 19 at 12:01 PM
News IconTaking A Closer Look at Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - August 17 at 3:42 PM
News IconA Closer Look at Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - August 16 at 3:43 PM
News IconShares Moving Up to a Recent High: Antares Pharma Inc. (NASDAQ:ATRS) - Post News (NASDAQ:ATRS)
www.kentuckypostnews.com - August 16 at 3:43 PM
capitalcube.com logoETF’s with exposure to Antares Pharma, Inc. : August 16, 2016 (NASDAQ:ATRS)
www.capitalcube.com - August 16 at 12:16 PM
News IconSmall Cap Update on: Antares Pharma Inc. (NASDAQ:ATRS) - Duncan Research (NASDAQ:ATRS)
www.duncanindependent.com - August 15 at 3:42 PM
capitalcube.com logoAntares Pharma, Inc. :ATRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:ATRS)
www.capitalcube.com - August 15 at 3:42 PM
capitalcube.com logoAntares Pharma, Inc. :ATRS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:ATRS)
www.capitalcube.com - August 15 at 3:42 PM
streetinsider.com logoAntares Pharma's (ATRS) CFO Resigns - StreetInsider.com (NASDAQ:ATRS)
www.streetinsider.com - August 11 at 3:43 PM

Social

Antares Pharma (NASDAQ:ATRS) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff